<DOC>
	<DOCNO>NCT01796132</DOCNO>
	<brief_summary>Background : The childbearing year time increase vulnerability onset mood disorder woman high prevalence exposure antidepressant drug pregnancy postpartum report . However , lack information regard milk transfer safety drug breastfed infant related fear adverse event suck infant factor responsible stop prematurely breast-feeding avoid drug therapy . Selective serotonin reuptake inhibitor ( SSRI ) selective serotonin noradrenaline reuptake inhibitor ( SNRI ) frequently prescribe antidepressant drug pregnancy post-partum period . They exhibit wide interpatient variability concentration profile relate numerous environmental , stereochemical , demographic genetic influence might alter level exposure breastfed newborn . Limited information available regard safety use antidepressant drug lactation , generally derive small study . A comprehensive description distribution quantification milk large cohort patient various influence result impact milk concentration lack . Objectives : The current proposal address primary objective quantify range concentration citalopram , escitalopram , sertraline , fluoxetine , paroxetine , fluvoxamine , duloxetine venlafaxine mother plasma breast milk relation genetic polymorphism , stereochemistry , demographic environmental factor large cohort depressive mother . This enable derive exposure breast-fed child take account variability therefore well adjust treatment potential influence . As secondary objective , examine neurodevelopmental outcome sub-set infant subject SSRI/SNRI utero and/or breastfeed birth , 6 , 18 36 month , compare control population infant subject treatment . Expected Results : The propose strategy offer new information regard expect level drug exposure associate combination risk factor help optimize security rationalizing use antidepressant treatment lactate woman . Hence , research safety use drug develop child area great public health significance .</brief_summary>
	<brief_title>Antidepressants During Pregnancy Lactation : Pharmacokinetics Clinical Implications</brief_title>
	<detailed_description>see brief summary</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Patients plan deliver 5 maternity involve study ; Mothers treatment SSRI/SNRI ( fluvoxamine , fluoxetine , paroxetine , duloxetine , citalopram , escitalopram , sertraline venlafaxine ) ; Mothers intent breastfeed child ; Ability understand willingness sign write informed consent document plasma milk withdrawal pharmacogenetic testing . For neurodevelopment followup part , baby Maternity Lausanne , Morges Geneva expose SSRI/SNRI enrol . A control group infant socioeconomic status subset expose patient recruit Maternity Hospital Lausanne . Mothers &lt; 18 year age patient ; Infants gestational age &lt; 34 week ; Mothers give birth infant major malformation ; Inability communicate due language problem mother ; Patients socioeconomic context make close monitoring child mother relative possible .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Depression</keyword>
	<keyword>Lactation</keyword>
	<keyword>Breastfeeding</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Antidepressant</keyword>
</DOC>